DD261363A5 - Neue polyhydroxylierte und hochfluorierte verbindungen, deren herstellung und verwendung als oberflaechenaktive stoffe - Google Patents

Neue polyhydroxylierte und hochfluorierte verbindungen, deren herstellung und verwendung als oberflaechenaktive stoffe Download PDF

Info

Publication number: DD261363A5
Authority: DD; German Democratic Republic
Prior art keywords: octyl; propanoyl; hexyl; ethyl; group
Prior art date: 1986-07-29

Application number

DD87305442A

Other languages

German (de)

English (en)

Inventor

Brigitte Charpiot

Jacques Greiner

Maurice Le Blanc

Alexandre Manfredi

Jean Riess

Leila Zarif

Original Assignee

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-07-29

Filing date

1987-07-28

Publication date

1988-10-26

1987-07-28 Application filed by K filed Critical K

1988-10-26 Publication of DD261363A5 publication Critical patent/DD261363A5/de

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 91
238000002360 preparation method Methods 0.000 title claims abstract description 31
239000013543 active substance Substances 0.000 title 1
239000000203 mixture Substances 0.000 claims abstract description 41
239000004094 surface-active agent Substances 0.000 claims abstract description 31
238000000034 method Methods 0.000 claims abstract description 26
125000001153 fluoro group Chemical group F* 0.000 claims abstract description 12
229920005862 polyol Polymers 0.000 claims abstract description 11
150000003077 polyols Chemical class 0.000 claims abstract description 11
125000004429 atom Chemical group 0.000 claims abstract description 8
150000002170 ethers Chemical class 0.000 claims abstract description 8
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 7
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 5
125000001246 bromo group Chemical group Br* 0.000 claims abstract description 4
229910052801 chlorine Inorganic materials 0.000 claims abstract description 4
239000000811 xylitol Substances 0.000 claims description 43
229960002675 xylitol Drugs 0.000 claims description 43
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 38
239000007858 starting material Substances 0.000 claims description 33
-1 polyoxyethylene Polymers 0.000 claims description 29
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
239000000243 solution Substances 0.000 claims description 26
125000002252 acyl group Chemical group 0.000 claims description 17
239000000839 emulsion Substances 0.000 claims description 15
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
239000006185 dispersion Substances 0.000 claims description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
150000001412 amines Chemical class 0.000 claims description 11
125000001424 substituent group Chemical group 0.000 claims description 11
150000002148 esters Chemical class 0.000 claims description 10
125000000217 alkyl group Chemical group 0.000 claims description 9
239000005720 sucrose Substances 0.000 claims description 9
150000001263 acyl chlorides Chemical class 0.000 claims description 8
229910052799 carbon Inorganic materials 0.000 claims description 8
125000001309 chloro group Chemical group Cl* 0.000 claims description 8
235000000346 sugar Nutrition 0.000 claims description 8
150000008064 anhydrides Chemical class 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 7
150000001408 amides Chemical class 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 6
238000010511 deprotection reaction Methods 0.000 claims description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
125000001488 beta-D-galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims description 5
229960002920 sorbitol Drugs 0.000 claims description 5
229930006000 Sucrose Natural products 0.000 claims description 4
125000005647 linker group Chemical group 0.000 claims description 4
210000000056 organ Anatomy 0.000 claims description 4
QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 4
125000004417 unsaturated alkyl group Chemical group 0.000 claims description 4
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
206010028980 Neoplasm Diseases 0.000 claims description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
239000003633 blood substitute Substances 0.000 claims description 3
150000001721 carbon Chemical group 0.000 claims description 3
239000002872 contrast media Substances 0.000 claims description 3
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 3
229960000367 inositol Drugs 0.000 claims description 3
239000008101 lactose Substances 0.000 claims description 3
BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 claims description 3
239000003921 oil Substances 0.000 claims description 3
230000010410 reperfusion Effects 0.000 claims description 3
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 3
LWRNQOBXRHWPGE-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4a,5,5,6,6,7,7,8,8a-heptadecafluoro-8-(trifluoromethyl)naphthalene Chemical class FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(C(F)(F)F)(F)C(F)(F)C(F)(F)C(F)(F)C21F LWRNQOBXRHWPGE-UHFFFAOYSA-N 0.000 claims description 2
KKKPPIZSICDRDW-UHFFFAOYSA-N 1,2,2,3,4,4,5,6,6,8,8,9,9,10-tetradecafluoro-7,10-bis(trifluoromethyl)adamantane Chemical class FC1(F)C(C2(F)F)(F)C(F)(F)C3(F)C(F)(F)C1(F)C(C(F)(F)F)(F)C2(C(F)(F)F)C3(F)F KKKPPIZSICDRDW-UHFFFAOYSA-N 0.000 claims description 2
XQRRSUIMAAZUTJ-UHFFFAOYSA-N 1,3,4,5,6,7,8-heptafluoroisoquinoline Chemical class FC1=C(F)C(F)=C(F)C2=C(F)C(F)=NC(F)=C21 XQRRSUIMAAZUTJ-UHFFFAOYSA-N 0.000 claims description 2
GNWCYGORHVILIN-UHFFFAOYSA-N FC(C(C(F)=C(C1=C(C(F)=C2F)F)F)=NC1=C2F)(F)F Chemical class FC(C(C(F)=C(C1=C(C(F)=C2F)F)F)=NC1=C2F)(F)F GNWCYGORHVILIN-UHFFFAOYSA-N 0.000 claims description 2
239000002671 adjuvant Substances 0.000 claims description 2
150000001312 aldohexoses Chemical class 0.000 claims description 2
150000001320 aldopentoses Chemical class 0.000 claims description 2
201000011510 cancer Diseases 0.000 claims description 2
239000008148 cardioplegic solution Substances 0.000 claims description 2
230000002490 cerebral effect Effects 0.000 claims description 2
238000002512 chemotherapy Methods 0.000 claims description 2
238000007796 conventional method Methods 0.000 claims description 2
238000007887 coronary angioplasty Methods 0.000 claims description 2
150000003999 cyclitols Chemical class 0.000 claims description 2
230000002526 effect on cardiovascular system Effects 0.000 claims description 2
210000002257 embryonic structure Anatomy 0.000 claims description 2
239000000499 gel Substances 0.000 claims description 2
150000002574 ketohexoses Chemical class 0.000 claims description 2
150000002581 ketopentoses Chemical class 0.000 claims description 2
239000004530 micro-emulsion Substances 0.000 claims description 2
UWEYRJFJVCLAGH-UHFFFAOYSA-N perfluorodecalin Chemical class FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C21F UWEYRJFJVCLAGH-UHFFFAOYSA-N 0.000 claims description 2
239000002798 polar solvent Substances 0.000 claims description 2
229920001451 polypropylene glycol Polymers 0.000 claims description 2
230000001681 protective effect Effects 0.000 claims description 2
238000001959 radiotherapy Methods 0.000 claims description 2
210000000582 semen Anatomy 0.000 claims description 2
238000003860 storage Methods 0.000 claims description 2
238000001356 surgical procedure Methods 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims description 2
210000001519 tissue Anatomy 0.000 claims description 2
239000013256 coordination polymer Substances 0.000 claims 2
KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 claims 1
229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
125000000524 functional group Chemical group 0.000 claims 1
208000028867 ischemia Diseases 0.000 claims 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 5
239000001301 oxygen Substances 0.000 abstract description 5
229910052760 oxygen Inorganic materials 0.000 abstract description 5
239000000460 chlorine Substances 0.000 abstract description 4
239000000969 carrier Substances 0.000 abstract description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract description 2
239000001257 hydrogen Substances 0.000 abstract description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
238000002844 melting Methods 0.000 description 16
230000008018 melting Effects 0.000 description 16
238000004587 chromatography analysis Methods 0.000 description 14
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 13
150000002905 orthoesters Chemical class 0.000 description 13
229920001993 poloxamer 188 Polymers 0.000 description 13
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
238000001953 recrystallisation Methods 0.000 description 10
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
239000000377 silicon dioxide Substances 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 7
229960003082 galactose Drugs 0.000 description 7
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
239000003480 eluent Substances 0.000 description 6
238000001704 evaporation Methods 0.000 description 6
230000008020 evaporation Effects 0.000 description 6
WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 5
229910052794 bromium Inorganic materials 0.000 description 5
229910052736 halogen Inorganic materials 0.000 description 5
150000002367 halogens Chemical class 0.000 description 5
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 4
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
229940126657 Compound 17 Drugs 0.000 description 4
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
229930182478 glucoside Natural products 0.000 description 4
150000008131 glucosides Chemical class 0.000 description 4
239000000047 product Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000001914 filtration Methods 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
239000011737 fluorine Substances 0.000 description 3
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical group FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 3
150000002243 furanoses Chemical class 0.000 description 3
229930182830 galactose Natural products 0.000 description 3
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
238000010992 reflux Methods 0.000 description 3
FSOCDJTVKIHJDC-OWOJBTEDSA-N (E)-bis(perfluorobutyl)ethene Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)\C=C\C(F)(F)C(F)(F)C(F)(F)C(F)(F)F FSOCDJTVKIHJDC-OWOJBTEDSA-N 0.000 description 2
MOSKUAXZYLAGNS-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalene hydrate Chemical compound O.C1CCCC2CCCCC21 MOSKUAXZYLAGNS-UHFFFAOYSA-N 0.000 description 2
KZEDJZPHTUJISI-UHFFFAOYSA-N 4-fluorodecan-2-ol Chemical compound CCCCCCC(F)CC(C)O KZEDJZPHTUJISI-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
229930091371 Fructose Natural products 0.000 description 2
239000005715 Fructose Substances 0.000 description 2
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
229940125810 compound 20 Drugs 0.000 description 2
229940125833 compound 23 Drugs 0.000 description 2
ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
239000008103 glucose Substances 0.000 description 2
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
125000000896 monocarboxylic acid group Chemical group 0.000 description 2
208000031225 myocardial ischemia Diseases 0.000 description 2
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
229950011087 perflunafene Drugs 0.000 description 2
UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
150000003214 pyranose derivatives Chemical class 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
239000002904 solvent Substances 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
NZXAVWBNLOQPGY-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-hexadecafluoro-4a,8a-bis(trifluoromethyl)naphthalene Chemical class FC(F)(F)C12C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C2(F)F NZXAVWBNLOQPGY-UHFFFAOYSA-N 0.000 description 1
ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
101710134784 Agnoprotein Proteins 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical class CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
241000251730 Chondrichthyes Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
GWESVXSMPKAFAS-UHFFFAOYSA-N Isopropylcyclohexane Chemical compound CC(C)C1CCCCC1 GWESVXSMPKAFAS-UHFFFAOYSA-N 0.000 description 1
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical group 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001323 aldoses Chemical class 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
230000001101 cardioplegic effect Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229940126543 compound 14 Drugs 0.000 description 1
229940126208 compound 22 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000006196 deacetylation Effects 0.000 description 1
238000003381 deacetylation reaction Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
238000010586 diagram Methods 0.000 description 1
125000006159 dianhydride group Chemical group 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
150000002402 hexoses Chemical class 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
150000002972 pentoses Chemical class 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000003058 plasma substitute Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000005855 radiation Effects 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
229910001958 silver carbonate Inorganic materials 0.000 description 1
229910001923 silver oxide Inorganic materials 0.000 description 1
GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
- C07C43/1787—Unsaturated ethers containing hydroxy or O-metal groups containing six-membered aromatic rings and having unsaturation outside the aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
- C09K23/007—Organic compounds containing halogen
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
- C09K23/56—Glucosides; Mucilage; Saponins
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/004—Surface-active compounds containing F

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Materials Engineering (AREA)
Crystallography & Structural Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Hematology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)
Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Furan Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Polyethers (AREA)
Noodles (AREA)
Steroid Compounds (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

DD87305442A 1986-07-29 1987-07-28 Neue polyhydroxylierte und hochfluorierte verbindungen, deren herstellung und verwendung als oberflaechenaktive stoffe DD261363A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR8611084A FR2602774B1 (fr)	1986-07-29	1986-07-29	Nouvelles molecules amphiphiles polyhydroxylees et perfluoroalkylees ayant des proprietes tensioactives

Publications (1)

Publication Number	Publication Date
DD261363A5 true DD261363A5 (de)	1988-10-26

Family

ID=9337904

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD87305442A DD261363A5 (de)	1986-07-29	1987-07-28	Neue polyhydroxylierte und hochfluorierte verbindungen, deren herstellung und verwendung als oberflaechenaktive stoffe

Country Status (17)

Country	Link
US (1)	US4985550A (el)
EP (1)	EP0255443B1 (el)
JP (1)	JPH0816106B2 (el)
CN (1)	CN87105263A (el)
AT (1)	ATE81507T1 (el)
AU (1)	AU608761B2 (el)
CA (1)	CA1315778C (el)
DD (1)	DD261363A5 (el)
DE (1)	DE3782210T2 (el)
DK (1)	DK392687A (el)
ES (1)	ES2052594T3 (el)
FR (1)	FR2602774B1 (el)
GR (1)	GR3006524T3 (el)
IE (1)	IE61102B1 (el)
NO (1)	NO169542C (el)
NZ (1)	NZ221232A (el)
PT (1)	PT85425B (el)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1223324B (it) *	1987-10-28	1990-09-19	Ausimont Spa	Microemulsioni acquose comprendenti perfluoropolieteri funzionali
US5055562A (en) *	1988-02-01	1991-10-08	Biomira, Inc.	Fluorocarbon chain-containing antigenic conjugates
US5023327A (en) *	1988-02-27	1991-06-11	Daikin Industries Ltd.	Fluorine-containing glycoside and its use
EP0375610A3 (en) *	1988-12-19	1992-01-02	Ciba-Geigy Ag	Perfluoroalkylthioglycosides
US5733572A (en) *	1989-12-22	1998-03-31	Imarx Pharmaceutical Corp.	Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US6001335A (en) *	1989-12-22	1999-12-14	Imarx Pharmaceutical Corp.	Contrasting agents for ultrasonic imaging and methods for preparing the same
US20020150539A1 (en) *	1989-12-22	2002-10-17	Unger Evan C.	Ultrasound imaging and treatment
US5585112A (en)	1989-12-22	1996-12-17	Imarx Pharmaceutical Corp.	Method of preparing gas and gaseous precursor-filled microspheres
US5542935A (en)	1989-12-22	1996-08-06	Imarx Pharmaceutical Corp.	Therapeutic delivery systems related applications
US6146657A (en) *	1989-12-22	2000-11-14	Imarx Pharmaceutical Corp.	Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US6551576B1 (en)	1989-12-22	2003-04-22	Bristol-Myers Squibb Medical Imaging, Inc.	Container with multi-phase composition for use in diagnostic and therapeutic applications
US5776429A (en) *	1989-12-22	1998-07-07	Imarx Pharmaceutical Corp.	Method of preparing gas-filled microspheres using a lyophilized lipids
US5656211A (en) *	1989-12-22	1997-08-12	Imarx Pharmaceutical Corp.	Apparatus and method for making gas-filled vesicles of optimal size
US5922304A (en)	1989-12-22	1999-07-13	Imarx Pharmaceutical Corp.	Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US6088613A (en)	1989-12-22	2000-07-11	Imarx Pharmaceutical Corp.	Method of magnetic resonance focused surgical and therapeutic ultrasound
US5580575A (en) *	1989-12-22	1996-12-03	Imarx Pharmaceutical Corp.	Therapeutic drug delivery systems
US5305757A (en) *	1989-12-22	1994-04-26	Unger Evan C	Gas filled liposomes and their use as ultrasonic contrast agents
FR2665705B1 (fr) *	1990-08-09	1993-07-30	Atta	Nouveaux derives fluores amphiphiles a structure telomere, leur procede de preparation et leur utilisation dans des preparations a usage biomedical.
US5874062A (en) *	1991-04-05	1999-02-23	Imarx Pharmaceutical Corp.	Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en)	1991-04-05	1993-04-27	Unger Evan C	Low density microspheres and their use as contrast agents for computed tomography
FR2677360B1 (fr) *	1991-06-05	1995-04-14	Atta	Composes amphiphiles perfluoroalkyles du phosphore, leurs preparations et leurs applications notamment dans le domaine biomedical.
FR2679150A1 (fr) *	1991-07-17	1993-01-22	Atta	Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
MX9205298A (es) *	1991-09-17	1993-05-01	Steven Carl Quay	Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
US6875420B1 (en)	1991-09-17	2005-04-05	Amersham Health As	Method of ultrasound imaging
US5409688A (en) *	1991-09-17	1995-04-25	Sonus Pharmaceuticals, Inc.	Gaseous ultrasound contrast media
US6723303B1 (en)	1991-09-17	2004-04-20	Amersham Health, As	Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane
US5621144A (en) *	1991-11-29	1997-04-15	Isis Innovation Limited	Fluorinated compounds as oxygen transport agents
GB9125454D0 (en) *	1991-11-29	1992-01-29	Isis Innovation	Oxygen transport agents
EP0633875B1 (en) *	1992-04-03	1997-01-02	Gist-Brocades N.V.	Selective n-acylation of amino alcohols
US5846516A (en) *	1992-06-03	1998-12-08	Alliance Pharmaceutial Corp.	Perfluoroalkylated amphiphilic phosphorus compounds: preparation and biomedical applications
US5350359A (en) *	1992-07-16	1994-09-27	Temple University Of The Commonwealth System Of Higher Education	Control, treatment and/or diagnosis of physiological conditions with degassed perfluorocarbon liquid
FR2694559B1 (fr) *	1992-08-06	1994-10-28	Atta	Nouveaux dérivés amphiphiles d'aminoacides ou de peptides, leur procédé de préparation et leur utilisation dans des préparations à usage biomédical.
IL108416A (en)	1993-01-25	1998-10-30	Sonus Pharma Inc	Colloids with phase difference as contrast ultrasound agents
CZ191695A3 (en) *	1993-01-25	1996-05-15	Sonus Pharma Inc	Biologically compatible contrast agent, process of its preparation and representation method by ultrasound
US5824781A (en) *	1993-08-16	1998-10-20	Hsia; Jen-Chang	Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5725839A (en) *	1993-08-16	1998-03-10	Hsia; Jen-Chang	Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
TW381022B (en)	1993-08-16	2000-02-01	Hsia Jen Chang	Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5736121A (en) *	1994-05-23	1998-04-07	Imarx Pharmaceutical Corp.	Stabilized homogenous suspensions as computed tomography contrast agents
FR2720943B1 (fr) *	1994-06-09	1996-08-23	Applic Transferts Technolo	Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US5562893A (en) *	1994-08-02	1996-10-08	Molecular Biosystems, Inc.	Gas-filled microspheres with fluorine-containing shells
US5730955A (en) *	1994-08-02	1998-03-24	Molecular Biosystems, Inc.	Process for making gas-filled microspheres containing a liquid hydrophobic barrier
US5965109A (en) *	1994-08-02	1999-10-12	Molecular Biosystems, Inc.	Process for making insoluble gas-filled microspheres containing a liquid hydrophobic barrier
US6743779B1 (en)	1994-11-29	2004-06-01	Imarx Pharmaceutical Corp.	Methods for delivering compounds into a cell
US5830430A (en) *	1995-02-21	1998-11-03	Imarx Pharmaceutical Corp.	Cationic lipids and the use thereof
US5997898A (en) *	1995-06-06	1999-12-07	Imarx Pharmaceutical Corp.	Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US5874481A (en) *	1995-06-07	1999-02-23	Alliance Pharmaceutical Corp.	Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US6521211B1 (en)	1995-06-07	2003-02-18	Bristol-Myers Squibb Medical Imaging, Inc.	Methods of imaging and treatment with targeted compositions
US6139819A (en) *	1995-06-07	2000-10-31	Imarx Pharmaceutical Corp.	Targeted contrast agents for diagnostic and therapeutic use
US5667809A (en) *	1995-06-07	1997-09-16	Alliance Pharmaceutical Corp.	Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US6231834B1 (en)	1995-06-07	2001-05-15	Imarx Pharmaceutical Corp.	Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US5611344A (en) *	1996-03-05	1997-03-18	Acusphere, Inc.	Microencapsulated fluorinated gases for use as imaging agents
HU226714B1 (en) *	1996-03-05	2009-07-28	Acusphere	Microencapsulated fluorinated gases for use as imaging agents
WO1997040679A1 (en)	1996-05-01	1997-11-06	Imarx Pharmaceutical Corp.	Methods for delivering compounds into a cell
FR2750134B1 (fr) *	1996-06-20	1998-08-14	Ceca Sa	1-c-perfluoroalkyl glycosides, procede de preparation et utilisations
US5837221A (en) *	1996-07-29	1998-11-17	Acusphere, Inc.	Polymer-lipid microencapsulated gases for use as imaging agents
US6414139B1 (en)	1996-09-03	2002-07-02	Imarx Therapeutics, Inc.	Silicon amphiphilic compounds and the use thereof
US5846517A (en)	1996-09-11	1998-12-08	Imarx Pharmaceutical Corp.	Methods for diagnostic imaging using a renal contrast agent and a vasodilator
DK0977597T3 (da) *	1996-09-11	2003-05-05	Imarx Pharmaceutical Corp	Forbedrede fremgangsmåder til diagnostisk billeddannelse ved hjælp af et kontrastmiddel og en vasodilatator.
US5834519A (en)	1996-10-11	1998-11-10	Wayne State University	Stabilized gas-supersaturated emulsions and suspensions
US5907017A (en) *	1997-01-31	1999-05-25	Cornell Research Foundation, Inc.	Semifluorinated side chain-containing polymers
US6537246B1 (en) *	1997-06-18	2003-03-25	Imarx Therapeutics, Inc.	Oxygen delivery agents and uses for the same
US6120751A (en)	1997-03-21	2000-09-19	Imarx Pharmaceutical Corp.	Charged lipids and uses for the same
US6090800A (en) *	1997-05-06	2000-07-18	Imarx Pharmaceutical Corp.	Lipid soluble steroid prodrugs
US6143276A (en) *	1997-03-21	2000-11-07	Imarx Pharmaceutical Corp.	Methods for delivering bioactive agents to regions of elevated temperatures
US6416740B1 (en)	1997-05-13	2002-07-09	Bristol-Myers Squibb Medical Imaging, Inc.	Acoustically active drug delivery systems
US5980936A (en) *	1997-08-07	1999-11-09	Alliance Pharmaceutical Corp.	Multiple emulsions comprising a hydrophobic continuous phase
US6548047B1 (en)	1997-09-15	2003-04-15	Bristol-Myers Squibb Medical Imaging, Inc.	Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) *	1997-12-18	2000-09-26	Imarx Pharmaceutical Corp.	Optoacoustic contrast agents and methods for their use
US20010003580A1 (en)	1998-01-14	2001-06-14	Poh K. Hui	Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
DE19948651B4 (de) *	1999-09-29	2006-10-05	Schering Ag	Para- und diamagnetische perfluorhaltige Verbindungen enthaltende galenische Formulierungen, deren Herstellung und Verwendung
GB2364702A (en) *	2000-07-17	2002-02-06	Unilever Plc	Perfluoroalkyl amphiphilic fabric treatment compounds
US7008535B1 (en) *	2000-08-04	2006-03-07	Wayne State University	Apparatus for oxygenating wastewater
WO2003097717A1 (fr) *	2002-05-16	2003-11-27	Daikin Industries, Ltd.	Composes actifs-surface non ionique soluble dans l'eau contenant du fluor, et utilisation et procede de preparation desdits composes
US7025697B2 (en) *	2003-11-26	2006-04-11	New Archery Products Corp.	Blade steering apparatus
US8012457B2 (en) *	2004-06-04	2011-09-06	Acusphere, Inc.	Ultrasound contrast agent dosage formulation
CN100396369C (zh) *	2006-03-02	2008-06-25	翟健	一种杂化非离子氟表面活性剂及其合成方法
MX2010004116A (es) *	2007-10-16	2010-07-02	Tyco Fire Products Lp	Fluoroalquenil poli[1,6]glicosidos.
US20120309853A1 (en) *	2011-06-06	2012-12-06	E I Du Pont De Nemours And Company	Aldohexose-based fluoroadditives
DE102013102239A1 (de) *	2013-03-06	2014-09-11	Universität Zu Köln	Carbosilanhaltiger Feuerlöschschaum
CN105238567B (zh) *	2015-10-10	2017-11-17	泉州市福达科技咨询有限公司	一种环保型含氟清洗剂及其制备方法
FR3072246B1 (fr) *	2017-10-13	2020-06-12	Biodesiv Efnium	Polymere antimicrobien pour semences animales

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2891052A (en) *	1956-04-10	1959-06-16	Rohm & Haas	Anhydrosorbityl amides and process of preparation
DE1468176A1 (de) *	1963-01-08	1968-12-12	Lepetit Spa	Verfahren zur Herstellung von nichtzyklischen Xylit-Estern
US3839318A (en) *	1970-09-27	1974-10-01	Rohm & Haas	Process for preparation of alkyl glucosides and alkyl oligosaccharides
IT967894B (it) *	1971-09-27	1974-03-11	Fmc Corp	Composti anti macchia a base di poliuretani fluorurati e proces so per la loro applicazione a prodotti tessili
US3952066A (en) *	1972-07-07	1976-04-20	Thiokol Corporation	Derivatives of perfluoroalkyl iodide-allyl glycidyl ether adducts
US4089804A (en) *	1976-12-30	1978-05-16	Ciba-Geigy Corporation	Method of improving fluorinated surfactants
JPS601175A (ja) *	1983-06-16	1985-01-07	Daikin Ind Ltd	アスコルビン酸誘導体
JPS604127A (ja) *	1983-06-21	1985-01-10	Daikin Ind Ltd	抗菌剤
JPS6028944A (ja) *	1983-07-25	1985-02-14	Kao Corp	新規なポリオ−ルエ−テル化合物およびその製造方法ならびにこれを含有する化粧料
JPS61107527A (ja) *	1984-10-31	1986-05-26	Matsushita Electric Ind Co Ltd	磁気記録媒体
GB8525871D0 (en) *	1985-10-21	1985-11-27	Tate & Lyle Plc	Chemical compound

1986
- 1986-07-29 FR FR8611084A patent/FR2602774B1/fr not_active Expired - Fee Related
1987
- 1987-07-28 NZ NZ221232A patent/NZ221232A/xx unknown
- 1987-07-28 IE IE204587A patent/IE61102B1/en not_active IP Right Cessation
- 1987-07-28 NO NO873168A patent/NO169542C/no unknown
- 1987-07-28 PT PT85425A patent/PT85425B/pt not_active IP Right Cessation
- 1987-07-28 DD DD87305442A patent/DD261363A5/de not_active IP Right Cessation
- 1987-07-28 DK DK392687A patent/DK392687A/da not_active Application Discontinuation
- 1987-07-28 US US07/078,626 patent/US4985550A/en not_active Expired - Lifetime
- 1987-07-28 AU AU76194/87A patent/AU608761B2/en not_active Ceased
- 1987-07-29 JP JP62191498A patent/JPH0816106B2/ja not_active Expired - Lifetime
- 1987-07-29 CA CA000543291A patent/CA1315778C/en not_active Expired - Fee Related
- 1987-07-29 ES ES87401769T patent/ES2052594T3/es not_active Expired - Lifetime
- 1987-07-29 EP EP87401769A patent/EP0255443B1/en not_active Expired - Lifetime
- 1987-07-29 DE DE8787401769T patent/DE3782210T2/de not_active Expired - Fee Related
- 1987-07-29 AT AT87401769T patent/ATE81507T1/de not_active IP Right Cessation
- 1987-07-29 CN CN198787105263A patent/CN87105263A/zh active Pending
1992
- 1992-12-14 GR GR920402898T patent/GR3006524T3/el unknown

Also Published As

Publication number	Publication date
GR3006524T3 (el)	1993-06-30
NO873168D0 (no)	1987-07-28
PT85425A (en)	1987-08-01
EP0255443A1 (en)	1988-02-03
IE872045L (en)	1988-01-29
AU7619487A (en)	1988-02-04
CA1315778C (en)	1993-04-06
NO169542B (no)	1992-03-30
JPS6399066A (ja)	1988-04-30
PT85425B (pt)	1990-06-29
DK392687A (da)	1988-01-30
DK392687D0 (da)	1987-07-28
ES2052594T3 (es)	1994-07-16
CN87105263A (zh)	1988-06-15
DE3782210D1 (de)	1992-11-19
FR2602774B1 (fr)	1990-10-19
IE61102B1 (en)	1994-10-05
ATE81507T1 (de)	1992-10-15
US4985550A (en)	1991-01-15
NZ221232A (en)	1990-08-28
NO873168L (no)	1988-02-01
FR2602774A1 (fr)	1988-02-19
AU608761B2 (en)	1991-04-18
JPH0816106B2 (ja)	1996-02-21
EP0255443B1 (en)	1992-10-14
DE3782210T2 (de)	1993-04-22
NO169542C (no)	1992-07-08

Publication	Publication Date	Title
DD261363A5 (de)	1988-10-26	Neue polyhydroxylierte und hochfluorierte verbindungen, deren herstellung und verwendung als oberflaechenaktive stoffe
DE69230235T2 (de)	2000-05-31	Kosmetische Zusammensetzung
DE69330096T2 (de)	2001-10-18	Neue medizinische zusammensetzung
EP0548261B1 (de)	1995-05-10	Spontan dispergierbares Konzentrat enthaltend einen Sterolester bzw. ein Sterolphosphatid
DE69107791T2 (de)	1995-11-09	Eine Dispersion von Lipidvesikeln enthaltende Kosmetika oder Arznei- bzw. Nahrungsmittel.
DE4439888A1 (de)	1995-05-24	Ultramikroemulsionen aus spontan dispergierbaren Konzentraten mit antitumoral wirksamen Xanthophyll-Estern
DE60215530T2 (de)	2007-05-31	Neues glykolipid, und heilmittel für autoimmunerkrankungen, das dieses als wirkstoff enthält
DE19747600C2 (de)	2001-07-26	Nichtionische Vitamin E-Derivate oder polyethoxylierte Vitamin E-Derivate und Verfahren zu ihrer Herstellung sowie ihre Verwendung
WO2010000713A1 (de)	2010-01-07	Linear-dendritische polyglycerolverbindungen, verfahren zu ihrer herstellung und ihre verwendung
EP0845475A1 (de)	1998-06-03	Inositolglykane mit insulinartiger Wirkung
DD269852A5 (de)	1989-07-12	Verfahren zur herstellung neuer beta-d- phenyl-thio-xyloside
DE69604631T2 (de)	2000-02-17	Prostaglandin-Derivate
EP0550704B1 (de)	1995-06-21	BIOTENSIDE ESTER MIT VITAMIN-D-VERBINDUNGEN; IHRE HERSTELLUNG UND AUFARBEITUNG ZU SPONTAN DISPERGIERBAREN kONZENTRATEN, SOWIE IHRE VERWENDUNG ZUR BEHANDLUNG VON TUMOREN
EP0609274B1 (de)	1997-09-03	Verfahren zur herstellung hellfarbiger alkyloligoglykosid-pasten
DE3609492A1 (de)	1986-09-25	Verfahren zur herstellung von phosphorsaeureestern
EP0185130B1 (de)	1988-03-02	Neue Derivate der 5-Alkoxy-2,4,6-trijod- und tribrom-isophthalsäure, Verfahren zu ihrer Herstellung und diese enthaltende Röntgenkontrastmittel
DE60016908T2 (de)	2005-12-08	Verwendung von Sulfoquinovosylglycerol-Derivativen als Immunosuppressiva
DE69509377T2 (de)	1999-11-18	Anthracyclin-derivate, die ein trifluormethylierte zuckereinheiten enthalten
EP0300960A2 (de)	1989-01-25	Neue pharmazeutische Präparate sowie neue Lactosylverbindungen und ihre Herstellung
DE2632115C2 (el)	1988-11-10
DE2501861C2 (de)	1984-02-09	3,4,6-Tri-O-acyl-2-desoxy-2-nicotinoylamino-1-O-nicotinoyl-&beta;-D-glucopyranosen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
EP0825191B1 (de)	2002-02-27	Chromanyl-ascorbinsäurederivate, deren Herstellung und Verwendung
AT388166B (de)	1989-05-10	Verfahren zur herstellung von neuen wasserloeslichen kohlenhydrat-derivaten
EP0410366A2 (de)	1991-01-30	Anthracyclin-Derivate
CH685674A5 (de)	1995-09-15	Ultramikroemulsionen aus spontan dispergierbaren Konzentraten mit pharmakologisch wirksamen Estern von Apocarotinolen.

Legal Events

Date	Code	Title	Description
1999-03-18	ENJ	Ceased due to non-payment of renewal fee